Oruka Therapeutics, Inc.
ORKAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeOruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I). The company carries a $5.59B market cap, placing it firmly in the mid-cap category. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions.
Market Cap
$5.59B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-37.20
EPS (TTM)
$-2.15
EPS (Fwd)
$-2.49
ROE
-27.3%
ROA
-18.9%
Cash
$388.8M
Total Debt
$1.8M
Free CF
-$56.1M
52W Change
537.5%
Annual Financials
Cash vs Debt
With $388.8M in cash and $1.8M in debt, ORKA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$56.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -27.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
With cash comfortably exceeding debt, ORKA has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Oruka Therapeutics, Inc.'s trajectory.